Case Report

Camrelizumab-Related Lethal Arrhythmias and Myasthenic Crisis in a Patient with Metastatic Thymoma

Table 1

Results of routine laboratory test.

ParameterNormal rangeBefore ICI useOn admissionDay 2Day 3Day 4Day 5

TnI (ng/mL)<0.0300.0113.9436.0563.046.020.8
CK-MB (ng/mL)0.60-6.301.10213.70233.6135.171.233.8
CK (U/L)38.0-174.020.48811.44051.32245.91259.5867.9
ALT (U/L)7-4012290273183
AST (U/L)13-3518805566155
Serum K (mmol/L)3.5-5.33.654.193.744.584.874.92
Serum Mg (mmol/L)0.75-1.020.820.850.850.991.011.04
Scr (μmol/L)41.0-81.058.473.443.296.296.2105.6
GFR (mL/min)75.0-300.094.172.2141.252.960.547.5
Arterial pH7.37-7.457.467.407.397.017.37
PaO2 (mmHg)83-1087678814864
PaCO2 (mmHg)35-4837403810436
BE (mmol/L)-3.0-3.02.31.81.3-7.3-4.1
D-dimer (ng/mL)<550.0586.2690.2780.1890.5900.4
NT-proBNP (pg/mL)<900.0308.81169.51208.22230.42508.5
WBC (×109/L)3.50-9.507.5218.819.321.422.620.5
Neu (%)45.0-75.071.888.289.889.690.189.8
RBC (×1012/L)3.80-5.104.03.983.913.823.563.81
Platelet (×109/L)100-300149100105989189
CRP (mg/L)<10<5.015.0320.023.2624.0026.80
ESR (mm/h)<2012303857
PCT (ng/mL)<0.05000.01000.180.200.04
Free T3 (pmol/L)3.1-6.83.83.3
Free T4 (pmol/L)9.5-24.513.316.1
TSH (μIU/mL)0.35-5.002.562.75

ICI: immune checkpoint inhibitor; TnI: troponin I; CK-MB: creatine kinase MB; CK: creatine kinase; ALT: alanine aminotransferase; AST: aspartate aminotransferase; K: potassium; Mg: magnesium; Scr: serum creatinine; GFR: glomerular filtration rate; PaO2: partial pressure of arterial oxygen; PaCO2: partial pressure of arterial carbon dioxide; BE: base excess; NT-proBNP: N-terminal pro-brain natriuretic peptide; WBC: white blood cell; Neu: neutrophil; RBC: red blood cell; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; PCT: procalcitonin; T3: triiodothyronine; T4: hyroxine, TSH: thyroid-stimulating hormone.